AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30872203 — intervention group
Group type: COMPARATOR
Intervention: Conservative group
Number of subjects: 150
Study 27767387 — intervention group
Group type: EXPERIMENTAL
Intervention: FDIS+MET
Number of subjects: 184
Study 27767387 — intervention group
Group type: COMPARATOR
Intervention: FDIS+placebo
Number of subjects: 184
Study 27767387 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+MET
Number of subjects: 184
Study 27767387 — intervention group
Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 184
Study 25998960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP) care
Number of subjects: 260
Study 25998960 — intervention group
Group type: COMPARATOR
Intervention: Standard care (medical practitioner led)
Number of subjects: 260
Study 23228571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 108 colony‐forming units per serving
Number of subjects: 179
Study 23228571 — intervention group
Group type: COMPARATOR
Intervention: Cereals without LF19
Number of subjects: 179
Study 22018188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 3 mg/day
Number of subjects: 31
Study 22018188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 19360864 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with low-dose tenecteplase (10 mg)
Number of subjects: 284
Study 19360864 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (control group)
Number of subjects: 284
Study 19360864 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with low-dose tenecteplase
Number of subjects: 284
Study 16297507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients without systemic steroids for the previous 3 months, treated with steroids for 4 weeks
Number of subjects: 49
Study 16297507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients with chronic steroid treatment both before and during the investigation
Number of subjects: 49
Study 16297507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients without systemic steroids for the previous 3 months, vaccinated after 4 weeks of steroid treatment
Number of subjects: 49
Study 16297507 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 49
Study 15349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Saucer shaped cavity and retentive grooves
Number of subjects: 550
Study 15349684 — intervention group
Group type: COMPARATOR
Intervention: Dovetail retentive cavity
Number of subjects: 550
Study 11140430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg by inhalation via Diskhaler
Number of subjects: 36
Study 11140430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg by inhalation via Diskus
Number of subjects: 36
Study 11140430 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 microg intravenously
Number of subjects: 36
Study 11140430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg twice daily via Diskhaler
Number of subjects: 36
Study 9466099 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF-GUARD
Number of subjects: 41
Study 9466099 — intervention group
Group type: COMPARATOR
Intervention: Relaxograph
Number of subjects: 41
Study 8402089 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel intervention
Number of subjects: 0
Study 8402089 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention
Number of subjects: 0
Study 3652469 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (50‐100 mg/d for 7 d)
Number of subjects: 16
Study 3652469 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/h for 8 h) after progesterone treatment
Number of subjects: 16
Study 3652469 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 16
Study 31978434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg orally 8 hourly up to 150 mg
Number of subjects: 300
Study 31978434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27591784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic artery (OA) blood flow measurement using ultrasound color doppler imaging (CDI)
Number of subjects: 65
Study 27591784 — intervention group
Group type: COMPARATOR
Intervention: Central retinal artery (CRA) blood flow measurement using ultrasound color doppler imaging (CDI)
Number of subjects: 65
Study 27591784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of OA blood flow in eyes with stage I ROP, stage II ROP, and without ROP
Number of subjects: 65
Study 26971823 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ethyl chloride
Number of subjects: 38
Study 26971823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water aerosol spray)
Number of subjects: 38
Study 24387624 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute loading infusion of magnesium sulphate (4 g over 60 minutes)
Number of subjects: 51
Study 24387624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute loading infusion of magnesium sulphate (4 g over 20 minutes)
Number of subjects: 51
Study 24387624 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute loading infusion of magnesium sulphate
Number of subjects: 51
Study 24387624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute loading infusion of magnesium sulphate
Number of subjects: 51
Study 21717444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenersen plus idarubicin (with or without cytarabine)
Number of subjects: 53
Study 21717444 — intervention group
Group type: COMPARATOR
Intervention: Cenersen inhibitors (acetaminophen and/or high dose antioxidants)
Number of subjects: 53
Study 19608835 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended perineural ropivacaine infusion (n = 24)
Number of subjects: 47
Study 19608835 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 23)
Number of subjects: 47
Study 17499389 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based spray sunscreen
Number of subjects: 139
Study 17499389 — intervention group
Group type: COMPARATOR
Intervention: Other sunscreens (not specified)
Number of subjects: 139
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (body height, weight, skinfolds, girths, lengths, breadths/lengths)
Number of subjects: 361
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis
Number of subjects: 361
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear discriminant analysis
Number of subjects: 361
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric characteristics
Number of subjects: 361
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Length and breadth/length parameters
Number of subjects: 361
Study 15228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold thicknesses
Number of subjects: 361
Study 11864853 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet (17% palm oil)
Number of subjects: 41
Study 11864853 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet (20.9% olive oil)
Number of subjects: 41
Study 11864853 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fat diet (12.5% sunflower oil)
Number of subjects: 41
Study 11864853 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fat diet (sunflower oil + 4-4.5 g fish oil/d)
Number of subjects: 41
Study 11864853 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 41
Study 11864853 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diets
Number of subjects: 41
Study 11279920 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine (10 mg twice daily)
Number of subjects: 135
Study 11279920 — intervention group
Group type: COMPARATOR
Intervention: flunarizine (5 mg once daily)
Number of subjects: 135
Study 11279920 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine
Number of subjects: 135
Study 11279920 — intervention group
Group type: COMPARATOR
Intervention: flunarizine
Number of subjects: 135
Study 11279920 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine and flunarizine
Number of subjects: 135
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate with aminosidine 12 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate with aminosidine 6 mg/kg/d
Number of subjects: 96
Study 7778155 — intervention group
Group type: COMPARATOR
Intervention: Comparison of aminosidine 12 mg/kg/d vs 6 mg/kg/d
Number of subjects: 96
Study 2182566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 114
Study 2182566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 114
Study 2182566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 6162348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream applied under occlusive dressing for 60 minutes
Number of subjects: 0
Study 6162348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 0
Study 31130260 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 648
Study 31130260 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 648
Study 31130260 — intervention group
Group type: COMPARATOR
Intervention: Continued methotrexate
Number of subjects: 648
Study 29234808 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (25-μg/d or 50-μg/d, titrated according to TSH levels during pregnancy)
Number of subjects: 600
Study 29234808 — intervention group
Group type: COMPARATOR
Intervention: Control (no levothyroxine treatment)
Number of subjects: 600
Study 26251480 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multimodal spine-strengthening exercise intervention (3 times a week for 6 months)
Number of subjects: 100
Study 26251480 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multimodal spine-strengthening exercise intervention
Number of subjects: 100
Study 26251480 — intervention group
Group type: COMPARATOR
Intervention: Monthly health education meetings and monthly calls from the study coordinator
Number of subjects: 100
Study 25844062 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 10
Study 25844062 — intervention group
Group type: COMPARATOR
Intervention: Control (no further training)
Number of subjects: 10
Study 22782483 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz stimulation
Number of subjects: 60
Study 22782483 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz stimulation
Number of subjects: 60
Study 22782483 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 60
Study 19588221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) at 10 Hz over left PMd and DLPFC
Number of subjects: 10
Study 19588221 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation over occipital cortex (OCC)
Number of subjects: 10
Study 17323666 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 180
Study 17323666 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 180
Study 14742609 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of quetiapine
Number of subjects: 9
Study 14742609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 14742609 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of quetiapine (open label phase)
Number of subjects: 9
Study 11851736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg casting prior to BTX‐A injections
Number of subjects: 34
Study 11851736 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting immediately after BTX‐A injections
Number of subjects: 34
Study 9870539 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 120
Study 9870539 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant prostheses
Number of subjects: 120
Study 7986398 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) in HIV-infected patients
Number of subjects: 17
Study 7986398 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) in seronegative volunteers
Number of subjects: 17
Study 7986398 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine monophosphate (ZDV-MP) in HIV-infected patients
Number of subjects: 17
Study 7986398 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine triphosphate (ZDV-TP) in both groups
Number of subjects: 17
Study 2680476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (75 g)
Number of subjects: 13
Study 2680476 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (plateau insulin concentration 50‐55 mU/l)
Number of subjects: 13
Study 2680476 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast
Number of subjects: 13
Study 30512231 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pole position
Number of subjects: 94
Study 30512231 — intervention group
Group type: COMPARATOR
Intervention: Double-pole position
Number of subjects: 94
Study 29170463 — intervention group
Group type: EXPERIMENTAL
Intervention: Luxury brand labels
Number of subjects: 0
Study 29170463 — intervention group
Group type: COMPARATOR
Intervention: Non-luxury brand labels
Number of subjects: 0
Study 26599634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-Dapsone (CD)
Number of subjects: 0
Study 23181592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 3344
Study 23181592 — intervention group
Group type: COMPARATOR
Intervention: Ingesting ≥1 hypertension medication at bedtime
Number of subjects: 3344
Study 23181592 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in asleep systolic BP mean
Number of subjects: 3344
Study 23181592 — intervention group
Group type: EXPERIMENTAL
Intervention: Asleep BP mean adjusted by awake mean
Number of subjects: 3344
Study 22152013 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose erythropoiesis-stimulating agents (ESA) (≥ 1 μg/kg/week)
Number of subjects: 32
Study 22152013 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose erythropoiesis-stimulating agents (ESA) (< 1 μg/kg/week)
Number of subjects: 32
Study 22152013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ESA dose (per μcg/kg/week)
Number of subjects: 32
Study 22152013 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose erythropoiesis-stimulating agents (ESA)
Number of subjects: 32
Study 19329456 — intervention group
Group type: EXPERIMENTAL
Intervention: Micrometric bioactive glass slurry
Number of subjects: 12
Study 19329456 — intervention group
Group type: COMPARATOR
Intervention: Nanometric bioactive glass slurry
Number of subjects: 12
Study 19329456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid bioactive glass slurry
Number of subjects: 12
Study 17115882 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflecting interview intervention group
Number of subjects: 24
Study 17115882 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 24
Study 15156393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 80 mg in 25 cc of saline
Number of subjects: 44
Study 11305844 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clozapine (Zenith Goldline Pharmaceuticals)
Number of subjects: 0
Study 11305844 — intervention group
Group type: COMPARATOR
Intervention: Clozaril (Novartis Pharmaceuticals)
Number of subjects: 0
Study 9438889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity flow administration of local anesthetic (Group 1)
Number of subjects: 600
Study 9438889 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection (Group 2)
Number of subjects: 600
Study 7705775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily for 4 weeks)
Number of subjects: 31
Study 7705775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 31
Study 7705775 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 31
Study 2650694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil providing about 3.2 g n-3 fatty acids per day
Number of subjects: 39
Study 2650694 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 39
Study 2650694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil
Number of subjects: 39
Study 278737 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing detergents (high content of surface active substances)
Number of subjects: 98
Study 278737 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified in the abstract)
Number of subjects: 98
Study 31867715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (ED90 estimated as 62.9 μg using truncated Dixon and Mood method)
Number of subjects: 30
Study 31867715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (ED90 estimated as 68 μg using isotonic regression method)
Number of subjects: 30
Study 31867715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 30
Study 31141159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glibenclamide (GBC)
Number of subjects: 213
Study 31141159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GBC or other sulfonylureas prior to stroke or after hospitalization)
Number of subjects: 213
Study 27040458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard corneal crosslinking (CXL)
Number of subjects: 149
Study 27040458 — intervention group
Group type: COMPARATOR
Intervention: Transepithelial iontophoresis-assisted CXL
Number of subjects: 149
Study 23875809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD; containing 150 mg calcium and 500 IU vitamin D/250 mL)
Number of subjects: 90
Study 23875809 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D-fortified doogh (CDD; containing 250 mg calcium and 500 IU vitamin D/250 mL)
Number of subjects: 90
Study 23875809 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 150 mg calcium and no detectable vitamin D/250 mL)
Number of subjects: 90
Study 21991736 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study 21991736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19797554 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride) applied before in-office bleaching
Number of subjects: 30
Study 19797554 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied before in-office bleaching
Number of subjects: 30
Study 19797554 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride)
Number of subjects: 30
Study 19797554 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 16895889 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (daily capsule containing 120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 µg Se, and 20 mg Zn)
Number of subjects: 3146
Study 16895889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3146
Study 16895889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline beta-carotene dietary intakes and plasma concentrations
Number of subjects: 3146
Study 16895889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma vitamin C
Number of subjects: 3146
Study 16895889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma selenium
Number of subjects: 3146
Study 14670572 — intervention group
Group type: EXPERIMENTAL
Intervention: Target saliency manipulation in visual search tasks
Number of subjects: 0
Study 14670572 — intervention group
Group type: EXPERIMENTAL
Intervention: Task difficulty manipulation in visual search tasks
Number of subjects: 0
Study 14670572 — intervention group
Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 0
Study 11712091 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg primaquine daily for 20 weeks
Number of subjects: 246
Study 11712091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 8703810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucaresol (oral doses; loading dose of 800 mg or 1200 mg for the first 4 days, followed by maintenance doses of 200 mg or 300 mg for the next 6 days; subsequent cohorts received 300 mg daily)
Number of subjects: 9
Study 8703810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1678631 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 18
Study 1678631 — intervention group
Group type: COMPARATOR
Intervention: Billroth I gastroduodenostomy
Number of subjects: 18
Study 1678631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 6861819 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (CRE above 1,400 reu)
Number of subjects: 44